Breast cancer mortality among women who have attended BreastScreen Norway, 1996-2023 [0.03%]
1996年至2023年参加挪威乳腺筛查计划的女性乳腺癌死亡率
Nataliia Moshina,Jonas Gjesvik,Xavier Castells et al.
Nataliia Moshina et al.
TLScope: a deep learning framework for quantifying tertiary lymphoid structures from H&E images reveals prognostic heterogeneity across breast cancer subtypes [0.03%]
基于H&E图像的深度学习框架量化乳腺癌次级淋巴结构的三级淋巴结构揭示不同亚型的预后异质性
Ruyuan Wang,Sunyan Liu,Yuxi Zhao et al.
Ruyuan Wang et al.
CD19+Ki67+B cells regulated by NAMPT as key modulators in triple-negative breast cancer with brain metastasis [0.03%]
三阴性乳腺癌脑转移中由NAMPT调节的CD19+Ki67+B细胞作为关键调节因子
Qiyi Zhou,Zhimin Zhu,Yuxin Zhao et al.
Qiyi Zhou et al.
Background: Among breast cancer subtypes, triple-negative breast cancer (TNBC) stands out for its aggressiveness and high frequency of brain metastases. However, the mechanisms driving BrM remain poorly understood. ...
Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: a single-arm, single-center, phase 2 study [0.03%]
注射用柴塞替尼联合氟维司群治疗既往内分泌治疗失败的激素受体阳性、HER2阴性晚期乳腺癌的单中心Ⅱ期临床研究
La Zou,Xianjun Tang,Pan Deng et al.
La Zou et al.
Background: Chidamide is an oral subtype-selective histone deacetylase inhibitor that has been used as an anti-cancer agent. This study evaluated the efficacy and safety of chidamide plus fulvestrant in the treatment of H...
Transcriptomic profiles from normal and tumor tissue samples reveal distinct venule populations and novel tumor endothelial cell markers in breast cancer [0.03%]
来自正常和肿瘤组织样本的转录组谱显示乳腺癌中独特的静脉细胞群和新的肿瘤内皮细胞标志物
Kathryn N Phoenix,Vijender Singh,Patrick A Murphy et al.
Kathryn N Phoenix et al.
Advances in the study of pyrotinib for the treatment of HER2-positive breast cancer [0.03%]
吡咯替尼治疗HER2阳性乳腺癌研究进展
Yan Li,Wen Wang,Yan Liang et al.
Yan Li et al.
HER2-positive breast cancer is characterized by aggressive tumor biology and intrinsic resistance to conventional therapies, underscoring the need for novel targeted treatment approaches. Pyrotinib, an irreversible pan-HER tyrosine kinase i...
FBR-NDs: a ferroptosis-inducing nanocomplex for targeted breast cancer therapy via immune modulation and redox-responsive drug delivery [0.03%]
铁死亡诱导纳米复合物通过免疫调节和氧化还原响应型药物输送进行靶向乳腺癌治疗
Jinjin Chen,Liang Ma,Ming Yin et al.
Jinjin Chen et al.
Background: The aim of this study was to develop and characterize a novel ferroptosis-inducing nanocomplex, FBR-NDs (Fe³⁺-BMS-1-R848 Nanodrugs), and to evaluate its anti-tumor effects in breast cancer cells through indu...
Pathway activity profiling can predict neoadjuvant endocrine therapy response in HR+ HER2- postmenopausal early stage breast cancer [0.03%]
通路活性谱分析可预测HR阳性HER2阴性绝经后早期乳腺癌患者新辅助内分泌治疗的反应
N de Gruil,A F de Groot,Y Wesseling-Rozendaal et al.
N de Gruil et al.
Outcomes of once daily and twice daily accelerated partial breast irradiation regimens in hormone receptor positive breast cancer: a single institution experience [0.03%]
单中心激素受体阳性乳腺癌患者每日一次和每日两次加速部分乳腺照射方案的结局分析
Tanun Jitwatcharakomol,Yevgeniya Gokun,Sierra J Daniel et al.
Tanun Jitwatcharakomol et al.
Background: Accelerated partial breast irradiation (APBI) has shown non-inferior local control compared to whole breast irradiation, but the optimal external-beam regimen is unclear. This study compares two APBI schedules...
Mechanism of IL-4 mediated RPL19 promoting malignant progression in HER2 positive breast cancer [0.03%]
乳腺癌中IL-4介导的RPL19促进HER2阳性乳腺癌恶性进展的作用机制研究
Nana Zhang,Jian Zhang,Junchao Shao et al.
Nana Zhang et al.